Tandem Diabetes Care Inc (OQ:TNDM)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: 11075 Roselle St
SAN DIEGO CA 92121-1204
Tel: N/A
Website: https://www.tandemdiabetes.com
IR: See website
Key People
Kim D. Blickenstaff
Chairman of the Board
Leigh A. Vosseller
Chief Financial Officer, Executive Vice President, Treasurer
David B. Berger
Chief Operating Officer, Executive Vice President, Assistant Secretary
Susan M. Morrison
Executive Vice President, Chief Administrative Officer
Elizabeth A. Gasser
Executive Vice President, Chief Strategy Officer
Brian B. Hansen
Chief Commercial Officer, Executive Vice President
Shannon M. Hansen
Senior Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
James A. Leal
Senior Vice President - Operations
Rick Carpenter
Chief Technical Officer
Business Overview
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The Company's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.
Financial Overview
For the three months ended 31 March 2022, Tandem Diabetes Care Inc revenues increased 25% to $175.9M. Net loss increased from $5M to $14.7M. Revenues reflect Infusion sets segment increase of 36% to $54.7M, Pump segment increase of 17% to $95.8M. Higher net loss reflects Research and development - Balancing val increase of 81% to $28.8M (expense), Other Selling, general and administ. increase of 25% to $61.4M (expense).
Employees: 2,000 as of Dec 31, 2021
Reporting Currency: U.S. Dollars
Enterprise value: $4,425M as of Mar 31, 2022
Annual revenue (TTM): $737.67M as of Mar 31, 2022
EBITDA (TTM): $24.54M as of Mar 31, 2022
Net annual income (TTM): $5.90M as of Mar 31, 2022
Free cash flow (TTM): $73.84M as of Mar 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 63,962,732 as of Apr 29, 2022
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.